Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Mylan Launches Generic EpiPen Priced at $300 for a Two-Pack

XTALKS VITALS NEWS

EpiPen

According to Mylan, the auto-injector is being sold at a wholesale acquisition cost (WAC), which is over 50 percent less expensive than the WAS of the branded EpiPen.

Share this!

December 19, 2016 | by Sarah Hand, M.Sc.

In an attempt to quell some of the drug pricing outrage that has surrounded the EpiPen, Mylan has released the first authorized generic of the device, priced at $300 for a two-pack of epinephrine injectors. According to Mylan, the auto-injector is being sold at a wholesale acquisition cost (WAC), which is over 50 percent less expensive than the WAS of the branded EpiPen.

The authorized generic is expected to hit pharmacies this week, with the same drug formulation and medical device design that users are familiar with. The EpiPen is used to treat anaphylaxis in patients with severe allergies, and has been on the market for almost 30 years.

“Americans are rightfully concerned about rising drug prices, and now more than ever patients and families across this country are standing at the pharmacy counter struggling to pay for their medications,” said Mylan CEO Heather Bresch in a press release issued by the company. “While it is important to understand the outdated and complex system that determines what someone pays for medicine in the U.S., hardworking families don't need an explanation, they need a solution.



“This is why we took decisive action with our EpiPen product and have launched the first generic version at half the WAC price. This unprecedented action, along with the enhancements we made to our patient access programs, will help patients and provide substantial savings to payors.”

Mylan plans to dedicate a salesforce of 275 representatives to sell the generic EpiPen. The company has also launched a savings card which will provide up to $25 in savings in out-of-pocket costs for eligible patients with commercial health insurance.

“As one of the world's largest generics companies, our medicines filled one out of 13 of all prescriptions in the U.S. last year – the equivalent of 21 billion doses – which is more than Pfizer, Merck, AstraZeneca, J&J, Sanofi and GSK combined,” continued Bresch. “We will continue to do our part to fight for changes that will make a difference in the lives of patients and remain deeply committed to serving patients in the severe allergy community by working to ensure that everyone who needs an EpiPen has access to one.”


Keywords: EpiPen, Generic, Drug Pricing


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.